文献速递呼吸衰竭与机械通气消化、代谢与肾脏急症

类风湿关节炎相关间质性肺病的定量CT扫描分析

Quantitative CT Scan Analysis in Rheumatoid Arthritis-Related Interstitial Lung Disease.
PubMed 文献 · Chest · 2024-11-09
一句话结论在RA-ILD患者中,CT肺纤维化定量评分与基线肺功能较差及死亡风险相关,系列扫描评分增加与后续死亡风险相关。

该研究在主要队列289例和验证队列50例类风湿关节炎相关间质性肺病(RA-ILD)患者中,采用数据驱动纹理分析(DTA)方法对CT扫描进行定量评估。基线DTA纤维化评分与FVC占预计值百分比呈中度负相关(主要队列rho=-0.55,验证队列rho=-0.50,均P<.001),与DLCO占预计值百分比亦呈负相关(主要队列rho=-0.67,验证队列rho=-0.65,均P<.001)。纵向DTA纤维化评分变化与FVC和DLCO变化相关(主要队列rho=-0.46和rho=-0.43,均P<.001)。Cox多变量模型显示基线DTA纤维化评分与死亡风险显著相关(主要队列HR 1.04,95%CI 1.03-1.05,P<.001;验证队列HR 1.06,95%CI 1.01-1.11,P=.026)。主要队列中,系列扫描DTA纤维化评分增加与死亡风险增加相关(HR 1.04,95%CI 1.01-1.06,P=.003),独立于基线DTA范围。作者认为,定量CT成像应考虑作为RA-ILD的临床和研究结局评估工具。

要点

  • 基线DTA纤维化评分与FVC占预计值百分比呈中度负相关:主要队列rho=-0.55,验证队列rho=-0.50,均P<.001。
  • 基线DTA纤维化评分与DLCO占预计值百分比呈负相关:主要队列rho=-0.67,验证队列rho=-0.65,均P<.001。
  • 基线DTA纤维化评分与死亡风险独立相关:主要队列HR 1.04(95%CI 1.03-1.05,P<.001),验证队列HR 1.06(95%CI 1.01-1.11,P=.026)。
  • 主要队列中,系列扫描DTA纤维化评分增加与死亡风险增加相关(HR 1.04,95%CI 1.01-1.06,P=.003),独立于基线DTA范围。
  • 纵向DTA纤维化评分变化与FVC和DLCO变化相关:主要队列rho=-0.46和rho=-0.43,均P<.001。

适用人群与场景

  • 主要队列289例和验证队列50例类风湿关节炎相关间质性肺病(RA-ILD)患者,评估CT定量纤维化评分的效用。

研究设计与关键结果

  • 研究设计:主要队列289例和验证队列50例RA-ILD患者,采用数据驱动纹理分析(DTA)方法定量评估CT扫描,分析纤维化范围定量评分与肺功能及生存的关联。
  • 基线DTA纤维化评分与FVC占预计值百分比呈中度负相关:主要队列rho=-0.55,验证队列rho=-0.50,均P<.001。
  • 基线DTA纤维化评分与DLCO占预计值百分比呈负相关:主要队列rho=-0.67,验证队列rho=-0.65,均P<.001。
  • 主要队列中,纵向DTA纤维化评分变化与FVC变化(rho=-0.46,P<.001)和DLCO变化(rho=-0.43,P<.001)相关。
  • Cox多变量模型(校正潜在影响变量)显示,基线DTA纤维化评分与死亡风险显著相关:主要队列HR 1.04(95%CI 1.03-1.05,P<.001),验证队列HR 1.06(95%CI 1.01-1.11,P=.026)。
  • 主要队列中,系列扫描DTA纤维化评分增加与死亡风险增加相关(HR 1.04,95%CI 1.01-1.06,P=.003),独立于基线DTA范围。

证据类型、等级与局限

  • 证据类型:基于两个队列(主要队列289例,验证队列50例)的定量CT分析研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,定量CT成像应考虑作为RA-ILD的临床和研究结局评估工具。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Quantitative CT imaging may be a useful predictor of outcome in rheumatoid arthritis-related interstitial lung disease (RA-ILD).

RESEARCH QUESTION: What is the utility of deep learning-based lung fibrosis quantitation on CT imaging in assessing disease severity, predicting mortality, and identifying progression in RA-ILD?

STUDY DESIGN AND METHODS: CT scans on a primary cohort of 289 patients and a validation cohort of 50 individuals with RA-ILD were assessed quantitatively by using the data-driven texture analysis (DTA) method. We examined associations between quantitative scores for extent of lung fibrosis and pulmonary function and survival.

RESULTS: DTA fibrosis score at baseline showed moderate negative correlation with FVC percent predicted (primary cohort rho = -0.55; validation cohort rho = -0.50; both, P < .001), and diffusing capacity for carbon monoxide percent predicted (primary cohort rho = -0.67; validation cohort rho = -0.65; both, P < .001). Longitudinal change in DTA fibrosis score was associated with changes in FVC and diffusing capacity for carbon monoxide in the primary cohort (rho = -0.46 and rho = -0.43, respectively; both, P < .001). Cox multivariable models adjusted for potentially influential variables showed that the baseline DTA fibrosis score was significantly associated with mortality risk (primary cohort hazard ratio [HR], 1.04 [95% CI, 1.03-1.05; P < .001]; validation cohort HR, 1.06 [95% CI, 1.01-1.11; P = .026]). In the primary cohort, the increase in DTA fibrosis score on sequential scans was associated with increased risk of mortality (HR, 1.04; 95% CI, 1.01-1.06; P = .003) independent of baseline DTA extent.

INTERPRETATION: In 2 cohorts of patients with RA-ILD, quantitative assessment of lung fibrosis on CT imaging was associated with worse lung function at baseline and risk of mortality. Increase in DTA-derived lung fibrosis score on sequential scans was associated with subsequent risk of mortality. Quantitative CT imaging should be considered for use as a clinical and research outcome assessment tool in RA-ILD.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Humphries SM, Adegunsoye A, Demoruelle MK, et al. Quantitative CT Scan Analysis in Rheumatoid Arthritis-Related Interstitial Lung Disease. Chest. 2024. PMID: 39528110. doi:10.1016/j.chest.2024.10.052

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。